For example, the dataset from Speake et al. comprised samples of patients with MS collected immediately before and 24 h after the administration of their first dose of IFNβ (Supplementary Fig. 3 [GEO ID GSE60424);29]. Here, IFNB1 is linked to myeloid sarcoma.